- Collagen Solutions has started patient enrolment into an open label extension study as part of the clinical development programme for ChondroMimetic, an osteochondral scaffold for the repair of cartilage defects in the knee.

Collagen Solutions said CE-marking for ChondroMimetic was achieved prior to the company's acquisition of the product and related IP, and this follow-up clinical study was a step towards reestablishing that CE-mark certification.

It said this extension study would supplement the original prospective safety and functional improvement data from 17 patients gathered in 2009 which supported CE Mark regulatory approval.

It said that 15 of the original 17 patients had confirmed enrolment to the extension study and initial clinical visits had already been initiated.

Collagen Solutions said it was targeting study completion before the end of the year.

Chief executive Jamal Rushdy said: "We are excited to begin the clinical assessment of long-term scaffold performance in patients who received the ChondroMimetic implant.

"To our knowledge, ChondroMimetic will be the only known, 'unpartnered' product with such long-term clinical evidence, significantly differentiating it from competing therapies.

"This extension study represents a critical step forward in our ChondroMimetic development programme, which has the potential to address 450,000 annual cartilage procedures and provide access to a US $500m-$1bn market opportunity via a novel, proprietary technology."

Story provided by